文献速递血脂与心血管预防

北欧2300万居民队列研究:SARS-CoV-2疫苗接种与心肌炎风险

SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
PubMed 文献 · JAMA Cardiol · 2022-01-01

结果显示,第二剂mRNA疫苗与心肌炎风险升高相关,年轻男性(16-24岁)风险最高,尤其是mRNA-1273。

要点

  • 第二剂BNT162b2和mRNA-1273均与心肌炎风险升高相关,调整IRR分别为1.75和6.57。
  • 16-24岁男性第二剂后风险最高,BNT162b2的IRR为5.31,mRNA-1273为13.83。
  • 每10万接种者中,第二剂BNT162b2后超额事件5.55例,mRNA-1273后18.39例。

核心结论

  • 第一剂和第二剂mRNA疫苗均与心肌炎和心包炎风险升高相关。
  • 接种两剂相同疫苗者中,16-24岁男性第二剂后心肌炎风险最高。
  • 该风险应与预防重症COVID-19的获益相权衡。

研究设计与样本

  • 四项队列研究按共同方案开展,结果通过荟萃分析合并。
  • 数据来自丹麦、芬兰、挪威和瑞典的全国健康登记数据库。

主要发现

  • 共识别1077例 incident 心肌炎事件和1149例心包炎事件。
  • 12岁及以上男女合并分析,第二剂BNT162b2的心肌炎调整IRR为1.75(95%CI 1.43-2.14),mRNA-1273为6.57(95%CI 4.64-9.28)。
  • 16-24岁男性第二剂BNT162b2的心肌炎调整IRR为5.31(95%CI 3.68-7.68),mRNA-1273为13.83(95%CI 8.08-23.68)。
  • 16-24岁男性第二剂BNT162b2后超额事件为5.55例/10万接种者(95%CI 3.70-7.39),mRNA-1273为18.39例/10万接种者(95%CI 9.05-27.72)。
  • 心包炎估计值与心肌炎相似。

临床怎么用

  • 临床医生应知晓mRNA疫苗接种后心肌炎风险,尤其是年轻男性第二剂后。
  • 评估心肌炎症状时应询问近期mRNA疫苗接种史。
  • 接种决策需个体化权衡心肌炎风险与重症COVID-19获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Reports of myocarditis after SARS-CoV-2 messenger RNA (mRNA) vaccination have emerged. OBJECTIVE: To evaluate the risks of myocarditis and pericarditis following SARS-CoV-2 vaccination by vaccine product, vaccination dose number, sex, and age. DESIGN, SETTING, AND PARTICIPANTS: Four cohort studies were conducted according to a common protocol, and the results were combined using meta-analysis. Participants were 23 122 522 residents aged 12 years or older. They were followed up from December 27, 2020, until incident myocarditis or pericarditis, censoring, or study end (October 5, 2021). Data on SARS-CoV-2 vaccinations, hospital diagnoses of myocarditis or pericarditis, and covariates for the participants were obtained from linked nationwide health registers in Denmark, Finland, Norway, and Sweden. EXPOSURES: The 28-day risk periods after administration date of the first and second doses of a SARS-CoV-2 vaccine, including BNT162b2, mRNA-1273, and AZD1222 or combinations thereof. A homologous schedule was defined as receiving the same vaccine type for doses 1 and 2. MAIN OUTCOMES AND MEASURES: Incident outcome events were defined as the date of first inpatient hospital admission based on primary or secondary discharge diagnosis for myocarditis or pericarditis from December 27, 2020, onward. Secondary outcome was myocarditis or pericarditis combined from either inpatient or outpatient hospital care. Poisson regression yielded adjusted incidence rate ratios (IRRs) and excess rates with 95% CIs, comparing rates of myocarditis or pericarditis in the 28-day period following vaccination with rates among unvaccinated individuals. RESULTS: Among 23 122 522 Nordic residents (81% vaccinated by study end; 50.2% female), 1077 incident myocarditis events and 1149 incident pericarditis events were identified. Within the 28-day period, for males and females 12 years or older combined who received a homologous schedule, the second dose was associated with higher risk of myocarditis, with adjusted IRRs of 1.75 (95% CI, 1.43-2.14) for BNT162b2 and 6.57 (95% CI, 4.64-9.28) for mRNA-1273. Among males 16 to 24 years of age, adjusted IRRs were 5.31 (95% CI, 3.68-7.68) for a second dose of BNT162b2 and 13.83 (95% CI, 8.08-23.68) for a second dose of mRNA-1273, and numbers of excess events were 5.55 (95% CI, 3.70-7.39) events per 100 000 vaccinees after the second dose of BNT162b2 and 18.39 (9.05-27.72) events per 100 000 vaccinees after the second dose of mRNA-1273. Estimates for pericarditis were similar. CONCLUSIONS AND RELEVANCE: Results of this large cohort study indicated that both first and second doses of mRNA vaccines were associated with increased risk of myocarditis and pericarditis. For individuals receiving 2 doses of the same vaccine, risk of myocarditis was highest among young males (aged 16-24 years) after the second dose. These findings are compatible with between 4 and 7 excess events in 28 days per 100 000 vaccinees after BNT162b2, and between 9 and 28 excess events per 100 000 vaccinees after mRNA-1273. This risk should be balanced against the benefits of protecting against severe COVID-19 disease.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. 2022. PMID: 35442390. doi:10.1001/jamacardio.2022.0583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。